Biogen, Sunesis in inflammatory and autoimmune disease pact
In what it says is the largest corporate alliance in its four-year history, Sunesis Pharmaceuticals (compound Tethering fragment-based technology) is collaborating with biopharmaceutical genetic engineering company Biogen to develop oral drugs to treat inflammatory and autoimmune diseases.
- Drug Discovery Tools
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com